|
| 37972067 | A peptidomimetic modulator of the Ca<sub>V</sub>2.2 N-type calcium channel for chronic pain. | Proc Natl Acad Sci U S A | 2023 |
| 37498871 | Identification and targeting of a unique Na<sub>V</sub>1.7 domain driving chronic pain. | Proc Natl Acad Sci U S A | 2023 |
| 36257093 | Generation of an iPSC line from a Pontocerebellar Hypoplasia 1B patient harboring a homozygous c.395 AÂ >Â C mutation in EXOSC3 along with a family matched control. | Stem Cell Res | 2022 |
| 35581326 | Heat shock protein Grp78/BiP/HspA5 binds directly to TDP-43 and mitigates toxicity associated with disease pathology. | Sci Rep | 2022 |
| 35452303 | Aptamers Targeting Hallmark Proteins of Neurodegeneration. | Nucleic Acid Ther | 2022 |
| 35514431 | Animal Models of Neurodegenerative Disease: Recent Advances in Fly Highlight Innovative Approaches to Drug Discovery. | Front Mol Neurosci | 2022 |
| 34141069 | <i>In Silico</i> Targeting of the Long Noncoding RNA MALAT1. | ACS Med Chem Lett | 2021 |
| 34525378 | Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells. | Stem Cell Reports | 2021 |
| 34757807 | Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. | Sci Transl Med | 2021 |
| 34458829 | Direct targeting of TDP-43, from small molecules to biologics: the therapeutic landscape. | RSC Chem Biol | 2021 |
| 32300293 | Corrigendum: Structural Insights Into TDP-43 and Effects of Post-translational Modifications. | Front Mol Neurosci | 2020 |
| 31971799 | Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins. | J Med Chem | 2020 |
| 33044808 | An Allosteric Modulator of RNA Binding Targeting the N-Terminal Domain of TDP-43 Yields Neuroprotective Properties. | ACS Chem Biol | 2020 |
| 30694439 | <sup>1</sup>H, <sup>15</sup>N and <sup>13</sup>C backbone assignment of apo TDP-43 RNA recognition motifs. | Biomol NMR Assign | 2019 |
| 31697467 | The Natural Flavonoid Naringenin Elicits Analgesia through Inhibition of NaV1.8 Voltage-Gated Sodium Channels. | ACS Chem Neurosci | 2019 |
| 31920533 | Structural Insights Into TDP-43 and Effects of Post-translational Modifications. | Front Mol Neurosci | 2019 |
| 31680630 | Evaluation of edonerpic maleate as a CRMP2 inhibitor for pain relief. | Channels (Austin) | 2019 |
| 30169422 | Betulinic acid, derived from the desert lavender Hyptis emoryi, attenuates paclitaxel-, HIV-, and nerve injury-associated peripheral sensory neuropathy via block of N- and T-type calcium channels. | Pain | 2019 |
| 31241884 | Small Molecule Targeting TDP-43's RNA Recognition Motifs Reduces Locomotor Defects in a <i>Drosophila</i> Model of Amyotrophic Lateral Sclerosis (ALS). | ACS Chem Biol | 2019 |
| 30933958 | Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy. | Pain | 2019 |
| 30525440 | (-)-Hardwickiic Acid and Hautriwaic Acid Induce Antinociception via Blockade of Tetrodotoxin-Sensitive Voltage-Dependent Sodium Channels. | ACS Chem Neurosci | 2019 |
| 28533518 | Blocking CRMP2 SUMOylation reverses neuropathic pain. | Mol Psychiatry | 2018 |
| 32714589 | A novel variant in <i>TAF1</i> affects gene expression and is associated with X-linked <i>TAF1</i> intellectual disability syndrome. | Neuronal Signal | 2018 |
| 30081699 | Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels. | Channels (Austin) | 2018 |
| 30141626 | A Chemical Biology Approach to Model Pontocerebellar Hypoplasia Type 1B (PCH1B). | ACS Chem Biol | 2018 |
| 29847471 | Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain. | Pain | 2018 |
| 28161890 | Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides. | Br J Pharmacol | 2018 |
| 28809766 | CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide. | Pain | 2017 |
| 28277940 | A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function. | Channels (Austin) | 2017 |
| 25846820 | (S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5. | Mol Neurobiol | 2016 |
| 27940916 | Hierarchical CRMP2 posttranslational modifications control NaV1.7 function. | Proc Natl Acad Sci U S A | 2016 |
| 27537210 | Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential. | Pain | 2016 |
| 26967696 | (S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. | Pain | 2016 |
| 25782368 | A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors. | Pain | 2015 |
| 25674050 | Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides. | Front Cell Neurosci | 2015 |
| 25104922 | The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth. | Front Cell Neurosci | 2014 |
| 25219851 | Discovery and characterization of small molecules that target the GTPase Ral. | Nature | 2014 |
| 23411397 | Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. | Bioorg Med Chem | 2013 |
| 24324135 | Structural basis for 2'-phosphate incorporation into glycogen by glycogen synthase. | Proc Natl Acad Sci U S A | 2013 |
| 23868973 | Mapping CRMP3 domains involved in dendrite morphogenesis and voltage-gated calcium channel regulation. | J Cell Sci | 2013 |
| 23711380 | Expression and purification of functional human glycogen synthase-1 (hGYS1) in insect cells. | Protein Expr Purif | 2013 |
| 22167676 | NMR studies of protein-RNA interactions. | Methods Mol Biol | 2012 |
| 22771232 | Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor. | Bioorg Med Chem | 2012 |
| 22828369 | CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy. | Mol Pain | 2012 |
| 22662308 | A PEPTIDE UNCOUPLING CRMP-2 FROM THE PRESYNAPTIC Ca(2+) CHANNEL COMPLEX DEMONSTRATES EFFICACY IN ANIMAL MODELS OF MIGRAINE AND AIDS THERAPY-INDUCED NEUROPATHY. | Transl Neurosci | 2012 |
| 21438548 | Target-specific support vector machine scoring in structure-based virtual screening: computational validation, in vitro testing in kinases, and effects on lung cancer cell proliferation. | J Chem Inf Model | 2011 |
| 22021038 | Discovery of a novel class of covalent inhibitor for aldehyde dehydrogenases. | J Biol Chem | 2011 |
| 21829088 | Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex. | Channels (Austin) | 2011 |
| 21851064 | Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. | J Med Chem | 2011 |
| 21875078 | Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion. | ACS Chem Biol | 2011 |